Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan

被引:142
作者
Uehara, Ritei [1 ,2 ]
Belay, Ermias D. [1 ]
Maddox, Ryan A. [1 ]
Holman, Robert C. [1 ]
Nakamura, Yosikazu [2 ]
Yashiro, Mayumi [2 ]
Oki, Izumi [2 ]
Ogino, Hirotaro [3 ]
Schonberger, Lawrence B. [1 ]
Yanagawa, Hiroshi [2 ]
机构
[1] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA
[2] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi, Japan
[3] Kansai Med Univ, Dept Pediat, Osaka, Japan
关键词
mucocutaneous lymph node syndrome; intravenous immunoglobulin; treatment failure; coronary artery abnormality; predictor;
D O I
10.1097/INF.0b013e31815922b5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Some Kawasaki disease (KD) patients do not respond to initial treatment with intravenous immunoglobulin (IVIG). The purpose of this study was to determine potential risk factors associated with IVIG nonresponse among KD patients in Japan. Methods: Data were obtained from questionnaires used for the 18th nationwide KD Survey of patients who visited hospitals in Japan from 2003 through 2004. Data for patients who met the case definition for KD and received 2 g/kg single infusion IVIG as the initial treatment within 10 days of illness were analyzed. IVIG nonresponders were defined as patients who needed secondary treatment after initial IVIG administration. Results: Among 15,940 KD patients in Japan during 2003-2004, 6330 patients received 2 g/kg single infusion IVIG within 10 days of illness onset. IVIG nonresponders accounted for 20.3% of them (n = 1286). Male sex [odds ratio (OR), 1.21, 95% confidence interval (0), 1.06-1.37], receipt of the initial IVIG before the fifth day of illness (OR: 1.89, 95% CI: 1.66-2.15), and having recurrent KD (OR: 1.38, 95% Cl: 1.00-1.90) were significantly associated with IVIG nonresponse. In addition, IVIG nonresponders had significantly higher risks for coronary artery aneurysms (OR: 10.38, 95% Cl: 6.98-15.45) or giant coronary artery aneurysms (OR: 54.06, 95% Cl: 12.84-227.65). Conclusions: Physicians should consider potential IVIG nonresponse among recurrent KD patients or KID patients diagnosed and treated before the fifth day of illness, particularly if they are boys and have laboratory values associated with nonresponse such as low platelet count, and elevated alanine aminotransferase and C-reactive protein. Some of these patients may benefit from administration of the alternative secondary treatment early during the illness along with the initial IVIG treatment.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 27 条
[1]  
[Anonymous], 1984, REP SUBC STAND DIAGN
[2]   Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) [J].
Ayusawa, M ;
Sonobe, T ;
Uemura, S ;
Ogawa, S ;
Nakamura, Y ;
Kiyosawa, N ;
Ishii, M ;
Harada, K .
PEDIATRICS INTERNATIONAL, 2005, 47 (02) :232-234
[3]   Intravenous gamma-globulin treatment and retreatment in Kawasaki disease [J].
Burns, JC ;
Capparelli, EV ;
Brown, JA ;
Newburger, JW ;
Glode, MP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (12) :1144-1148
[4]   Coronary artery dimensions may be misclassified as normal in Kawasaki disease [J].
de Zorzi, A ;
Colan, SD ;
Gauvreau, K ;
Baker, AL ;
Sundel, RP ;
Newburger, JW .
JOURNAL OF PEDIATRICS, 1998, 133 (02) :254-258
[5]   Immunoglobulin failure and retreatment in Kawasaki disease [J].
Durongpisitkul, K ;
Soongswang, J ;
Laohaprasitiporn, D ;
Nana, A ;
Prachuabmoh, C ;
Kangkagate, C .
PEDIATRIC CARDIOLOGY, 2003, 24 (02) :145-148
[6]   Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease [J].
Egami, Kimiyasu ;
Muta, Hiromi ;
Ishii, Masahiro ;
Suda, Kenji ;
Sugahara, Yoko ;
Iemura, Motofumi ;
Matsuishi, Toyojiro .
JOURNAL OF PEDIATRICS, 2006, 149 (02) :237-240
[7]   Thermometry in paediatric practice [J].
El-Rashdi, AS ;
Barry, W .
ARCHIVES OF DISEASE IN CHILDHOOD, 2006, 91 (04) :351-356
[8]   Prediction of non-responsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset [J].
Fukunishi, M ;
Kikkawa, M ;
Hamana, K ;
Onodera, T ;
Matsuzaki, K ;
Matsumoto, Y ;
Hara, J .
JOURNAL OF PEDIATRICS, 2000, 137 (02) :172-176
[9]   Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease [J].
Han, RK ;
Silverman, ED ;
Newman, A ;
McCrindle, BW .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (07) :694-699
[10]   Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy [J].
Ishii, M ;
Hashino, K ;
Iemura, M ;
Akagi, T ;
Kato, H .
PEDIATRICS INTERNATIONAL, 2001, 43 (03) :211-217